94 Congenital Heart Disease

Selected References

Akintuerk H, Mickel-Behnke I, Valeske W, et al. Stenting of the arterial duct and banding of the pulmonary arteries: basis of a combined stage I and stage II repair in HLHS. *Circulation*. 2002;105:1099-1103.

Allen HD, Shaddy RE, Penny DJ, et al. *Moss and Adams’ Heart Disease in Infants, Children and Adolescents*. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.

Alwan S, Reefhuis J, Rasmussen S, et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007;356;258s4-2692.

Ballard RA, Wernosky G. Cardiovascular system. In: Taeugsch HW, ed. Avery’s Diseases of the Newborn. Philadelphia, PA: Elsevier Saunders; 2005:779-901.

Brooks PA, Penny DJ. Management of the sick neonate with suspected heart disease. Early Hum Dev. 2008;84(3):155-159.

Centers for Disease Control and Prevention. Congenital heart disease screen. https://www.cdc.gov/ncbddd/heartdefects/hcp.html. Accessed January 21, 2019.

Dorfman AT, Marino BS, Wernovsky G, et al. Critical heart disease in the neonate: presentation and outcome at a tertiary care center. Pediatr Crit Care Med. 2008;9(2):193-202.

Galantowicz M, Cheatham JP. Lessons learned from the development of a new hybrid strategy for management of HLHS. *Pediatr Cardiol*. 2005;26:190-199.

Hofer LE, Freynschlag R, Leitner-Penedr G, et al. Levosimendan versus milrinone after corrective open-heart surgery in infants. Clinical trial NCT00549107. Leitz, Germany. https://clinicaltrials.gov/ct2/show/NCT00549107. Accessed January 21, 2019.

Jenkins PC, Flanagan MF, Sargent JD, et al. A comparison of treatment strategies for hypoplastic left heart syndrome using decision analysis. J Am Coll Cardiol. 2001;38:1181.

Karamlou T, Overman D, Hill K, et al. Stage I hybrid palliation for HLHS: assessment of contemporary patterns of use. *J Thorac Cardiovasc Surg*. 2015;180:195-202.

Landis BJ, Levey A, Levasseur SM, et al. Prenatal diagnosis of congenital heart disease and birth outcomes. *Pediatr Cardiol.* 2013;34(3):697-605.

Paradisis M, Jiang X, McLachlan J, et al. Population pharmacokinetics and dosing regimen design of milrinone in preterm infants. Arch Dis Child Fetal Neonatal ED. 2007;92:F204-F209.

Pendersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:b3569.

Perry LW, Neill CA, Ferencz C, Rubin JD, Loffredo CA. Infants with congenital heart disease: the cases. In: Ferencz C, Loffredo CA, Rubin JD, Magee CA, eds. Epidemiology of Congenital Heart Disease: The Baltimore-Washington Infant Heart Study 1981–1989. Mt. Kisco, NY: Futura; 1993:63-62

Richards AA, Garg V. Genetics of congenital heart disease. *Curr Cardiol Rev*. 2010;6(2):91-97.

Rosenthal A. Hypoplastic left heart syndrome. In: Moller JH, Hoffman JIE, eds. Pediatric Cardiovascular Medicine. New York, NY: Churchill Livingston; 2000.

Simsic JM, Reddy VS, Kanter KR, et al. Use of nesiritide (human B-type natriuretic peptide) in infants following cardiac surgery. Pediatr Cardiol. 2004;25:668-670.

Soufia M, Aoun J, Gorsane M, et al. SSRIs and pregnancy: a review of the literature. Encephale. 2010;36(6):513-516.

Tobias JD. B-type natriuretic peptide: diagnostic and therapeutic applications in infants and children. J Intensive Care Med. 2011;26:183-195.